Galmed Pharmaceuticals (GLMD) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Galmed Pharmaceuticals has amended its Standby Equity Purchase Agreement with YA II PN, LTD., allowing the company to issue and sell up to $20 million of its ordinary shares. This strategic move aims to enhance financial flexibility and could attract investor interest by providing a clearer pathway for capital infusion. The amendment underscores Galmed’s commitment to strengthening its financial standing while maintaining investor confidence.
For further insights into GLMD stock, check out TipRanks’ Stock Analysis page.